Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos (NYSE:GKOS) announced U.S. FDA approval of an NDA labeling supplement dated January 28, 2026 permitting re-administration of iDose TR under a repeat treatment protocol.
The approval follows Glaukos' 2025 supplement and is supported by clinical evidence showing no clinically significant corneal endothelial cell loss through three years and a safe, well-tolerated second administration over 12 months.
Glaukos (NYSE: GKOS) will release its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Management will discuss results in a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A live webcast link will be available at the company's investor website.
To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.
Glaukos (NYSE: GKOS) reported preliminary, unaudited net sales of approximately $143 million for Q4 2025 (up 36% year-over-year) and approximately $507 million for full year 2025 (up 32% year-over-year). Q4 sales mix: U.S. Glaucoma $86M (iDose TR $45M), International Glaucoma $33M, Corneal Health $24M. Full year mix: U.S. Glaucoma $299M (iDose TR $136M), International Glaucoma $122M, Corneal Health $86M. The company ended Q4 with approximately $283M in cash, cash equivalents and short-term investments and no debt. Glaukos reaffirmed 2026 net sales guidance of $600M–$620M. Preliminary results are subject to revision when final results are released after market close on Feb 17, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Glaukos (NYSE:GKOS) said its management will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 4:30 p.m. PT in San Francisco.
A live and archived webcast will be available in the Investors section of the company website for viewers who cannot attend in person.
Glaukos (NYSE:GKOS) said its management will participate in multiple investor conferences in November–December 2025, including UBS Global Healthcare (Nov 11, 2025, 10:15 a.m. ET, Palm Beach), Stifel Healthcare (Nov 12, 2025, 1:20 p.m. ET, New York), Stephens Annual Investment (Nov 18, 2025, 10:00 a.m. CT, Nashville), BTIG Ophthalmology Day (Dec 1, 2025, virtual) and Citi Global Healthcare (Dec 3, 2025, 1:45 p.m. ET, Miami).
A live and archived webcast for applicable events will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
Glaukos (NYSE: GKOS) reported record Q3 2025 net sales of $133.5M, up 38% YoY (37% constant currency), driven by glaucoma sales of $110.2M (+45% YoY) and U.S. glaucoma sales of $80.8M (+57% YoY). Gross margin was ~78% and non-GAAP gross margin ~84% for Q3 2025. GAAP net loss was $16.2M (loss of $0.28 per diluted share); non-GAAP net loss was $9.2M (loss of $0.16 per diluted share). Cash and equivalents plus short-term investments totaled ~$277.5M and the company reported no debt. Management raised 2025 net sales guidance to $490M–$495M and provided preliminary 2026 net sales guidance of $600M–$620M.
Glaukos (NYSE:GKOS) announced FDA approval of Epioxa HD / Epioxa, the first FDA‑approved incision‑free topical drug therapy for keratoconus, a rare sight‑threatening corneal disease. Approval was supported by two randomized, double‑masked Phase 3 trials that randomized over 400 patients and met primary efficacy endpoints with favorable tolerability. Epioxa uses sequential topical formulations activated by UV in an oxygen‑enriched environment to perform corneal cross‑linking without removing the epithelium. Glaukos expects commercial availability in Q1 2026 and plans investments in patient awareness, access programs, and co‑pay assistance.
Glaukos (NYSE:GKOS) will feature technologies and scientific posters at the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, October 18–20, 2025, and will exhibit onsite at booth #2921.
Highlighted content includes glaucoma posters on Travoprost intracameral implant (iDose TR) with up to 36-month topical medication reduction and Month 12 cataract-surgery outcomes, corneal health Phase 3 data for epithelium-on CXL, and presentations on oxygen-supplemented/topography-guided epithelium-on CXL and IRIS Registry analysis of CXL failure rates. Two timed presentations: Oct 17, 2025 at 1:55 p.m. ET and Oct 18, 2025 at 11:18 a.m. ET. Abstracts available at www.aao.org/annual-meeting.
Glaukos (NYSE:GKOS) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Management will discuss results on a conference call and simultaneous webcast at 1:30 p.m. PT / 4:30 p.m. ET on October 29, 2025.
A live webcast link will be available at http://investors.glaukos.com. To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has broken ground on a new 200,000 square-foot research, development, and manufacturing facility in Huntsville, Alabama. The project represents a planned investment of over $80 million and is expected to create more than 150 full-time jobs in the region.
The company selected Huntsville from over 100 potential sites worldwide, citing the area's strong talent base and vibrant business climate. Located in Cummings Research Park, the facility will be built on 25 acres with an option for an additional 15 acres for future expansion. The project is scheduled for completion by 2030 and aims to strengthen U.S. manufacturing capabilities while supporting Glaukos' long-term growth plans.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
